查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1547928

全球 DNA 修復药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global DNA Repair Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

全球 DNA 修復药物市场需求预计将从 2023 年的 70.2 亿美元达到近 247.9 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 15.05%。

DNA 损伤导致遗传物质结构改变。它会导致 DNA 结构中包含缺陷和异常，从而导致 DNA 突变。突变发生在编码必需蛋白质或酵素的基因。因此，DNA 损伤阻碍了 DNA 的正常功能和性能，导致遗传性疾病的发生。然而，人体有能力修復受损的 DNA 序列。 DNA 修復是一系列过程的组合，包括识别发生突变的细胞以及纠正编码基因组中涉及的 DNA 分子。某些药物如聚 ADP 核糖聚合酶 (PARP) 抑制剂可用于增强人体的 DNA 修復机制。 DNA修復药物支持与DNA损伤和遗传异常相关的治疗。

市场动态

全球癌症盛行率正在迅速上升。基因突变会导致细胞生长失控，进而导致癌症。癌症是导致全球大量死亡的主要疾病之一。癌症盛行率的不断上升正在推动全球 DNA 修復药物市场的发展。此外，越来越多地采用先进的下一代技术来治疗癌症和其他遗传疾病，这也刺激了需求。重点厂商正在大规模投入研发，寻找有效的药物解决方案来支持DNA修復机制。主要市场参与者采取的策略正在推动全球市场。 COVID-19 大流行正在支持药物开发的研发，这可能会增强全球 DNA 修復药物市场。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球 DNA 修復药物市场的各个细分市场进行了包容性评估。 DNA 修復药物产业的成长和趋势为本研究提供了整体方法。

市场区隔

DNA 修復药物市场报告的这一部分提供了国家和地区层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人群以及即将到来的机会。

依药物类型

  • 塔拉佐帕尼
  • 奥拉帕尼
  • 尼拉帕尼
  • 卢卡帕尼
  • 其他药物类型

按申请

  • 乳癌
  • 卵巢癌
  • 腹膜癌
  • 输卵管癌
  • 其他应用

按配销通路

  • 医院药房
  • 零售药局
  • 其他分销管道

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲 DNA 修復药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。 DNA修復药物市场的主要参与者包括阿斯特捷利康公司、Onxeo、强生公司、FoRx Therapeutics、艾伯维、Artios Pharma Limited、辉瑞公司、Breakpoint Therapeutics、Luciole Pharmaceuticals、默克公司、ClovisOncology Inc.、葛兰素史克公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：DNA 修復药物 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按药物类型分類的市场吸引力分析
    • 市场吸引力分析：依应用分类
    • 按配销通路分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球 DNA 修復药物市场分析：依药物类型

  • 按药物类型概述
  • 历史和预测数据
  • 依药物类型分析
  • 塔拉佐帕尼
  • 奥拉帕尼
  • 尼拉帕尼
  • 卢卡帕尼
  • 其他药物类型

第 6 章：全球 DNA 修復药物市场分析：按应用分类

  • 概述：按应用
  • 历史和预测数据
  • 分析：按应用
  • 乳癌
  • 卵巢癌
  • 腹膜癌
  • 输卵管癌
  • 其他应用

第 7 章：全球 DNA 修復药物市场分析：按分销管道

  • 配销通路概述
  • 历史和预测数据
  • 按配销通路分析
  • 医院药房
  • 零售药局
  • 其他分销管道

第 8 章：全球 DNA 修復药物市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 9 章：DNA 修復药物公司的竞争格局

  • DNA修復药物市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 10 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • AstraZeneca Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Onxeo
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Johnson & Johnson
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • FoRx Therapeutics
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • AbbVie
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Artios Pharma Limited
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Pfizer Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Breakpoint Therapeutics
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Luciole Pharmaceuticals
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Merck KGaA
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • ClovisOncology Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • GlaxoSmithKline Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR11212424

The global demand for DNA Repair Drugs Market is presumed to reach the market size of nearly USD 24.79 Billion by 2032 from USD 7.02 Billion in 2023 with a CAGR of 15.05% under the study period 2024-2032.

DNA damage causes alteration of structure in genetic material. It causes the inclusion of deficiencies and abnormalities in the DNA structure, which leads to mutations in the DNA. The mutations take place in the genes coding for essential proteins or enzymes. Thus DNA damage hampers the proper functioning and performance of the DNA resulting in the development of genetic disorders. However, the human body is capable of repairing damaged DNA sequences. DNA repairing is a combination of processes altogether that includes identification of cells where the mutation has occurred and the correction of DNA molecules that are involved in the encoding genome. Certain drugs such as poly ADP ribose polymerase (PARP) inhibitors are used to enhance the body's DNA repairing mechanism. DNA repair drugs support the treatments related to DNA damage and genetic abnormalities.

MARKET DYNAMICS

The prevalence of cancer is rising rapidly across the globe. Mutations in the genes cause uncontrolled cell growth leading to cancer. Cancer is one of the major diseases responsible for a large number of deaths across the globe. The increasing prevalence of cancer is propelling the global DNA repair drugs market. Furthermore, the growing adoption of advanced next-generation technologies to treat cancer and other genetic diseases is fueling demand. The key manufacturers are investing in R & D on a large scale to find effective drug solutions to support the DNA repair mechanism. The strategies acquired by key market players are propelling the global market. COVID-19 pandemic is supporting the R & D in drug development that is likely to enhance the global DNA repair drugs market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of DNA Repair Drugs. The growth and trends of DNA Repair Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the DNA Repair Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

  • Talazoparib
  • Olaparib
  • Niraparib
  • Rucaparib
  • Other Drug Types

By Application

  • Breast Cancer
  • Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer
  • Other Applications

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the DNA Repair Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the DNA Repair Drugs market include AstraZeneca Plc, Onxeo, Johnson & Johnson, FoRx Therapeutics, AbbVie, Artios Pharma Limited, Pfizer Inc., Breakpoint Therapeutics, Luciole Pharmaceuticals, Merck KGaA, ClovisOncology Inc., GlaxoSmithKline Plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. DNA REPAIR DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Type
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY DRUG TYPE

  • 5.1. Overview By Drug Type
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Drug Type
  • 5.4. Talazoparib Historic and Forecast Sales By Regions
  • 5.5. Olaparib Historic and Forecast Sales By Regions
  • 5.6. Niraparib Historic and Forecast Sales By Regions
  • 5.7. Rucaparib Historic and Forecast Sales By Regions
  • 5.8. Other Drug Types Historic and Forecast Sales By Regions

6. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY APPLICATION

  • 6.1. Overview By Application
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Application
  • 6.4. Breast Cancer Historic and Forecast Sales By Regions
  • 6.5. Ovarian Cancer Historic and Forecast Sales By Regions
  • 6.6. Peritoneal Cancer Historic and Forecast Sales By Regions
  • 6.7. Fallopian Tube Cancer Historic and Forecast Sales By Regions
  • 6.8. Other Applications Historic and Forecast Sales By Regions

7. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1. Overview By Distribution Channel
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Distribution Channel
  • 7.4. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 7.5. Retail Pharmacies Historic and Forecast Sales By Regions
  • 7.6. Other Distribution Channels Historic and Forecast Sales By Regions

8. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE DNA REPAIR DRUGS COMPANIES

  • 9.1. DNA Repair Drugs Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF DNA REPAIR DRUGS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. AstraZeneca Plc
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Onxeo
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Johnson & Johnson
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. FoRx Therapeutics
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. AbbVie
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Artios Pharma Limited
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Pfizer Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Breakpoint Therapeutics
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Luciole Pharmaceuticals
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Merck KGaA
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. ClovisOncology Inc.
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments
  • 10.14. GlaxoSmithKline Plc
    • 10.14.1 Company Overview
    • 10.14.2 Company Revenue
    • 10.14.3 Products
    • 10.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Type (USD MN)
  • Talazoparib Market Sales By Geography (USD MN)
  • Olaparib Market Sales By Geography (USD MN)
  • Niraparib Market Sales By Geography (USD MN)
  • Rucaparib Market Sales By Geography (USD MN)
  • Other Drug Types Market Sales By Geography (USD MN)
  • Analysis By Application (USD MN)
  • Breast Cancer Market Sales By Geography (USD MN)
  • Ovarian Cancer Market Sales By Geography (USD MN)
  • Peritoneal Cancer Market Sales By Geography (USD MN)
  • Fallopian Tube Cancer Market Sales By Geography (USD MN)
  • Other Applications Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Other Distribution Channels Market Sales By Geography (USD MN)
  • Global DNA Repair Drugs Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of DNA Repair Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global DNA Repair Drugs Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Type
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Type (USD MN)
  • Talazoparib Market Sales By Geography (USD MN)
  • Olaparib Market Sales By Geography (USD MN)
  • Niraparib Market Sales By Geography (USD MN)
  • Rucaparib Market Sales By Geography (USD MN)
  • Other Drug Types Market Sales By Geography (USD MN)
  • Global Market Analysis By Application (USD MN)
  • Breast Cancer Market Sales By Geography (USD MN)
  • Ovarian Cancer Market Sales By Geography (USD MN)
  • Peritoneal Cancer Market Sales By Geography (USD MN)
  • Fallopian Tube Cancer Market Sales By Geography (USD MN)
  • Other Applications Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Other Distribution Channels Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.